Navigation Links
Regado Biosciences, Inc. Appoints World-Renowned Leader in Cardiovascular Research and Former Global Head of Cardiovascular Diseases for Merck & Co., to Board of Directors
Date:11/5/2013

BASKING RIDGE, N.J., Nov. 5, 2013 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced the appointment of Michael E. Mendelsohn, M.D., to the company's Board of Directors.  The appointment strengthens Regado's leadership team by infusing the Company with a world-renowned leader in cardiovascular research and clinical development as the Phase 3 REGULATE-PCI clinical trial is actively enrolling patients worldwide.

Dr. Mendelsohn brings to Regado an unparalleled combination of cardiovascular therapeutic expertise, large pharmaceutical company experience and academic achievement. Since June 2010, Dr. Mendelsohn has served as Senior Vice President and Global Franchise Head for Cardiovascular Diseases at Merck & Co.  While at Merck, he led research and development and global strategy for all cardiovascular programs from Discovery to Late Development. Prior to joining Merck in 2010, Dr. Mendelsohn spent 17 years at Tufts Medical Center, where he served as the first-ever Chief Scientific Officer and the Executive Director of the center's Molecular Cardiology Research Institute. Dr. Mendelsohn received his undergraduate degree in Chemistry and English from Amherst College and his M.D. from Harvard Medical School. He completed his residency in internal medicine and fellowship in cardiovascular medicine at the Brigham and Women's Hospital (BWH). From 1988 to 1993 Dr. Mendelsohn was a member of the faculty of the BWH Cardiology Division and an Assistant Professor of Medicine at Harvard Medical School. As a physician, scientist and international leader in molecular vascular biology, Dr. Mendelsohn has made major contributions to the field of molecular cardiology and vascular biology over the past three decades.

Dr. Mendelsohn stated, "I am honored to join Regado's Board and advise the company generally as it advances its business strategy and specifically on the pursuit of its clinical and discovery strategies.  I look forward to working closely with the superb Regado executive team and Board as the company executes the ongoing Phase 3 REGULATE-PCI study, which has the potential to bring an important and unique new two-component anticoagulant system to cardiologists performing coronary revascularization procedures.  The science behind REG1 and its reversal agent is novel and elegant and has the potential to improve both efficacy and safety in patients undergoing these procedures."

Dennis Podlesak, MBA, Regado's Board Chairman, stated, "We are delighted to have Dr. Mendelsohn join our board of directors.  We believe he will be a superb addition given his rich career background in the cardiovascular space along with his recent "big pharma" experience as the Global Franchise Head for Cardiovascular Disease while at Merck.  Mike's addition is entirely consistent with our plans to assemble the strongest team possible with the collective expertise to ensure Regado's success going forward as we focus on advancing Regado's lead product candidate, REG1, and its pipeline with the goal of significantly improving patient outcomes." 

ABOUT REGADO BIOSCIENCES
Regado Biosciences, Inc. is a biopharmaceutical company focused on the development of novel, first-in-class, actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications.  Regado is pioneering the development of two-component drug systems consisting of a therapeutic aptamer and its specific active control agent. The company's lead product candidate, REG1, is a two-component system consisting of pegnivacogin, an anticoagulant aptamer specifically targeting coagulation Factor IXa, and its complementary oligonucleotide active control agent, anivamersen.  REG1 is being developed for use in patients with a wide variety of acute coronary syndromes, or ACS, undergoing a percutaneous coronary intervention, or PCI, a hospital-based procedure used to mechanically open or widen obstructed coronary arteries. Regado's actively controllable product candidates have the potential to improve patient outcomes, enhance the patient experience and reduce overall treatment costs.  More information can be found at www.regadobio.com.

For more information on REGULATE-PCI, please visit:
http://www.clinicaltrials.gov/ct2/show/NCT01848106?term=Regado&rank=1

Contact:
Tiberend Strategic Advisors, Inc.

Investors - Joshua Drumm, Ph.D.
jdrumm@tiberend.com; (212) 375-2664
Media - Andrew Mielach
amielach@tiberend.com; (212) 375-2694


'/>"/>
SOURCE Regado Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Regado Biosciences, Inc. to Provide Third Quarter 2013 Financial Results
2. Regado Biosciences, Inc. to Present at Aegis Capital Vegas Healthcare Conference
3. Regado Biosciences, Inc. Announces Exercise of Over-Allotment Option
4. Regado Biosciences, Inc. Files Registration Statement for Proposed Initial Public Offering
5. Regado Biosciences, Inc. to Present at Needham & Companys 11th Annual Healthcare Conference in New York, NY
6. Regado Biosciences, Inc. to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston, MA
7. Jeeven BioSciences, Inc. Announces the Release of Its Neuro-XTM Serum-Free and Xeno-Free Tissue Culture Media
8. Biotechs Leading the Healthcare Sector - Alliqua, Pacific Biosciences, Oncothyreon, Keryx, Organovo
9. SAGE Labs, Inc. Licenses CRISPR/Cas9 genome engineering technology from Caribou Biosciences, Inc.
10. Pressure BioSciences, Inc. to Discuss Second Quarter 2013 Financial Results and Provide a Business Update
11. Pressure BioSciences, Inc. Closes Final Tranche of Series J Above Market Private Placement - Total Amount Raised in PIPE Slightly Exceeds $2 Million Goal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ... its endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression ... guides is transformative for performing systematic gain-of-function studies. , This complement to ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that ... Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... ... innovation and business process optimization firm for the life sciences and healthcare industries, ... conference in San Francisco. , The presentation, “Automating GxP Validation for Agile ...
Breaking Biology Technology:
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
(Date:3/30/2017)... , March 30, 2017 The research ... system for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D ... a new realm of speed and accuracy for use in identification, ... an affordable cost. ... ...
(Date:3/27/2017)... 2017  Catholic Health Services (CHS) has been ... (HIMSS) Analytics for achieving Stage 6 on the ... In addition, CHS previously earned a place in ... electronic medical record (EMR). "HIMSS Analytics ... EMR usage in an outpatient setting.  This recognition ...
Breaking Biology News(10 mins):